Skip to content
  • Home
  • Company
    • About Us
    • Leadership
    • Management
    • Board of Directors
    • Scientific
      Advisory Board
  • Science
    • Evorpacept
    • Publications
  • Pipeline
    • Clinical Trials
    • Expanded
      Access Policy
  • Careers
    • Current Jobs
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • IR Resources
  • Contact

ALX148 Blocks CD47 and Enhances Innate and Adaptive Antitumor Immunity with a Favorable Safety Profile

Post navigation

Previous: A Phase 1 Study of ALX148: CD47 Blockade in Combination with Anti-Cancer Antibodies to Bridge Innate and Adaptive Immune Responses for Advanced Malignancy
Next: Discovery of Monoclonal Antibodies Targeting Myeloid Checkpoint SIRPα to Enhance Anti-Tumor Immunity
TOP
  • Home
  • Company
    • About Us
    • Leadership
    • Management
    • Board of Directors
    • Scientific
      Advisory Board
  • Science
    • Evorpacept
    • Publications
  • Pipeline
    • Clinical Trials
    • Expanded
      Access Policy
  • Careers
    • Current Jobs
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • IR Resources
  • Contact
© ALX Oncology Inc., All rights reserved.
Privacy Policy Twitter LinkedIn